Skip to main content
Erschienen in:

01.08.2006 | Leitthema

Nichtkleinzelliges Lungenkarzinom

Palliative Chemotherapie im Stadium IV und bei Patienten mit Komorbidität

verfasst von: Dr. M. Reck, K.M. Deppermann, U. Gatzemeier, N. Niederle

Erschienen in: Die Onkologie | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aufgrund der hohen Inzidenz des nichtkleinzelligen Lungenkarzinoms in fortgeschrittenen Stadien stellt die systemische Therapie eine wichtige Behandlungsmaßnahme dieser Erkrankung dar. Durch Einführung neuer Medikamente konnte die Effektivität und die Verträglichkeit der Chemotherapie verbessert werden. Standard in der Erstlinientherapie ist eine platinbasierte Zweierkombination mit einem Drittgenerationszytostatikum über 4–6 Zyklen je nach Ansprechen. Weder eine Erweiterung der Kombination noch eine Verlängerung der Therapie führen zu einer Verbesserung der Ergebnisse. Eine Alternative in der Erstlinientherapie sind platinfreie Kombinationen von Drittgenerationszytostatika. Für Patienten in schlechtem Allgemeinzustand und alte Patienten mit Komorbidität ist eine Monotherapie mit Gemcitabin, Vinorelbin oder einem Taxan angezeigt. Eine modifizierte Kombinationstherapie sollte bei alten Patienten in gutem Allgemeinzustand geprüft werden. Als Therapieoptionen in der Zweitlinientherapie bieten sich Pemetrexed, Docetaxel oder der EGFR-Tyrosinkinaseinhibitor Erlotinib an.
Literatur
1.
Zurück zum Zitat Krebs in Deutschland (2004) 4. Überarbeitete und aktualisierte Ausgabe, Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Saarbrücken Krebs in Deutschland (2004) 4. Überarbeitete und aktualisierte Ausgabe, Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, Saarbrücken
2.
Zurück zum Zitat Mountain CF (1997) Revision in the the international system for staging of Lung Cancer. Chest 111: 1710–1717PubMed Mountain CF (1997) Revision in the the international system for staging of Lung Cancer. Chest 111: 1710–1717PubMed
3.
Zurück zum Zitat Non-small Cell Lung Cancer Collaborative Group (1995) A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899–909 Non-small Cell Lung Cancer Collaborative Group (1995) A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899–909
4.
Zurück zum Zitat Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828–836CrossRefPubMed Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59: 828–836CrossRefPubMed
5.
Zurück zum Zitat Rudd RM, Gower NH, Spiro SG et al. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142–153CrossRefPubMed Rudd RM, Gower NH, Spiro SG et al. (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIb or IV non-small cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23: 142–153CrossRefPubMed
6.
Zurück zum Zitat Crino L, Scagliotti GV, Ricci F et al. (1999) Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide and Cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–30.PubMed Crino L, Scagliotti GV, Ricci F et al. (1999) Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide and Cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522–30.PubMed
7.
Zurück zum Zitat Cardenal F, Lopez-Cabrerizo MP, Anton A et al. (1999) Randomized phase III study of Gemcitabine-Cisplatin versus Etoposide-Cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12–18PubMed Cardenal F, Lopez-Cabrerizo MP, Anton A et al. (1999) Randomized phase III study of Gemcitabine-Cisplatin versus Etoposide-Cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12–18PubMed
8.
Zurück zum Zitat Le Chevalier T, Brisgand D, Douillard JY et al (1996) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer : results of an European multicenter trial including 612 patients. J Clin Oncol 14: 687–688PubMed Le Chevalier T, Brisgand D, Douillard JY et al (1996) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer : results of an European multicenter trial including 612 patients. J Clin Oncol 14: 687–688PubMed
9.
Zurück zum Zitat Le Chevalier T, Brisgand D, Soria JC et al. (2001) Long term analysis of survival in the European randomized trial comparing Vinorelbine to Vindesine/Cisplatin and Vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6 (Suppl 1): 8–11 Le Chevalier T, Brisgand D, Soria JC et al. (2001) Long term analysis of survival in the European randomized trial comparing Vinorelbine to Vindesine/Cisplatin and Vinorelbine alone in advanced non-small cell lung cancer. Oncologist 6 (Suppl 1): 8–11
10.
Zurück zum Zitat Kubota K, Watanabe K, Kunitoh H et al. (2004) Phase III randomized trial of docetaxel plus cisplatin versus Vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254–261CrossRefPubMed Kubota K, Watanabe K, Kunitoh H et al. (2004) Phase III randomized trial of docetaxel plus cisplatin versus Vindesine plus cisplatin in patients with stage IV non-small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22: 254–261CrossRefPubMed
11.
Zurück zum Zitat Belani CP, Lee JS, Socinski MA (2005) Randomized phase III trial comparin cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16: 1069–1075CrossRefPubMed Belani CP, Lee JS, Socinski MA (2005) Randomized phase III trial comparin cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16: 1069–1075CrossRefPubMed
12.
Zurück zum Zitat Grigorescu AC, Draghici IN, Nitipir C et al. (2002) Gemcitabine and Carboplatin versus Cisplatin and Vinblastine in advanced non-small cell lung cancer stages III and IV: a phase III randomised trial. Lung Cancer 37: 9–14CrossRefPubMed Grigorescu AC, Draghici IN, Nitipir C et al. (2002) Gemcitabine and Carboplatin versus Cisplatin and Vinblastine in advanced non-small cell lung cancer stages III and IV: a phase III randomised trial. Lung Cancer 37: 9–14CrossRefPubMed
13.
Zurück zum Zitat Bonomi P, Kim K, Fairclough D et al. (2000) Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623–631PubMed Bonomi P, Kim K, Fairclough D et al. (2000) Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623–631PubMed
14.
Zurück zum Zitat Giaccone G, Splinter TA, Debruyne C et al. (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133–2141PubMed Giaccone G, Splinter TA, Debruyne C et al. (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133–2141PubMed
15.
Zurück zum Zitat Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92–98CrossRefPubMed Schiller JH, Harrington D, Belani CP et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92–98CrossRefPubMed
16.
Zurück zum Zitat Kelly K, Crowley J, Bunn PA Jr et al. (2001) Randomized phase III trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology group trial. J Clin Oncol 19: 3210–3218PubMed Kelly K, Crowley J, Bunn PA Jr et al. (2001) Randomized phase III trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology group trial. J Clin Oncol 19: 3210–3218PubMed
17.
Zurück zum Zitat Scagliotti GV, De Marinis F, Rimaldi M et al. (2002) Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285–4291CrossRefPubMed Scagliotti GV, De Marinis F, Rimaldi M et al. (2002) Phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol 20: 4285–4291CrossRefPubMed
18.
Zurück zum Zitat Fosella F, Pereira JR, von Pawel J et al. (2003) Randomized, multinational, phase III study of Docetaxel plus platinum combinations versus Vinorelbine plus Cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016–3024PubMed Fosella F, Pereira JR, von Pawel J et al. (2003) Randomized, multinational, phase III study of Docetaxel plus platinum combinations versus Vinorelbine plus Cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016–3024PubMed
19.
Zurück zum Zitat Alberola V, Camps C, Provencio M et al. (2003) Cisplatin plus Gemcitabine versus a Cisplatin-triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207–3213CrossRefPubMed Alberola V, Camps C, Provencio M et al. (2003) Cisplatin plus Gemcitabine versus a Cisplatin-triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207–3213CrossRefPubMed
20.
Zurück zum Zitat Greco FA, Gray JR Jr, Thompson DS et al. (2002) Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 95: 1279–1285CrossRefPubMed Greco FA, Gray JR Jr, Thompson DS et al. (2002) Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 95: 1279–1285CrossRefPubMed
21.
Zurück zum Zitat Laack E, Dickgreber N, Muller T et al. (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22: 2348–2356CrossRefPubMed Laack E, Dickgreber N, Muller T et al. (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22: 2348–2356CrossRefPubMed
22.
Zurück zum Zitat Delbaldo C, Michiels S, Syz N et al. (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 292: 499–500CrossRefPubMed Delbaldo C, Michiels S, Syz N et al. (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer: a meta-analysis. JAMA 292: 499–500CrossRefPubMed
23.
Zurück zum Zitat Smith IE, O‘Brien ME, Talbot DC et al. (2001) Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19: 1336–1343PubMed Smith IE, O‘Brien ME, Talbot DC et al. (2001) Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19: 1336–1343PubMed
24.
Zurück zum Zitat Socinski MA, Schell MJ, Peterman A et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIb/IV non-small cell lung cancer. J Clin Oncol 20: 1335–1343PubMed Socinski MA, Schell MJ, Peterman A et al. (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIb/IV non-small cell lung cancer. J Clin Oncol 20: 1335–1343PubMed
25.
Zurück zum Zitat Pfister DG, Johnson DH, Azzoli CG et al. (2004) American Society of Clinical Oncology Treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330–353CrossRefPubMed Pfister DG, Johnson DH, Azzoli CG et al. (2004) American Society of Clinical Oncology Treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22: 330–353CrossRefPubMed
26.
Zurück zum Zitat Georgoulias V, Samonis G, Papadakis E et al. (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34 (Suppl 4): 47–51CrossRefPubMed Georgoulias V, Samonis G, Papadakis E et al. (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34 (Suppl 4): 47–51CrossRefPubMed
27.
Zurück zum Zitat Kosmidis P, Mylonakis N, Nicolaides C et al. (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578–3585CrossRefPubMed Kosmidis P, Mylonakis N, Nicolaides C et al. (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20: 3578–3585CrossRefPubMed
28.
Zurück zum Zitat Stathopoulos GP, Veslemes M, Georgatou N et al. (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small cell lung cancer: a randomized phase III trial. Ann Oncol 15: 1048–1055CrossRefPubMed Stathopoulos GP, Veslemes M, Georgatou N et al. (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small cell lung cancer: a randomized phase III trial. Ann Oncol 15: 1048–1055CrossRefPubMed
29.
Zurück zum Zitat Tan EH, Szszesna A, Krzakowski M et al. (2005) Randomized study of vinorelbine – gemcitabine versus vinorelbine carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49: 233–240CrossRefPubMed Tan EH, Szszesna A, Krzakowski M et al. (2005) Randomized study of vinorelbine – gemcitabine versus vinorelbine carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49: 233–240CrossRefPubMed
30.
Zurück zum Zitat Georgoulias V, Ardavanis A, Tsiafaki X et al. (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 23: 2937–2945CrossRefPubMed Georgoulias V, Ardavanis A, Tsiafaki X et al. (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 23: 2937–2945CrossRefPubMed
31.
Zurück zum Zitat Pujl JL, Breton JL, Gervais R et al. (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16: 602–610CrossRefPubMed Pujl JL, Breton JL, Gervais R et al. (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16: 602–610CrossRefPubMed
32.
Zurück zum Zitat Kosmidis P, Kalofonos C, Syrigos K et al. (2005) Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer. Lung Cancer 49 (Suppl 2): 34 (O-094)CrossRef Kosmidis P, Kalofonos C, Syrigos K et al. (2005) Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer. Lung Cancer 49 (Suppl 2): 34 (O-094)CrossRef
33.
Zurück zum Zitat D’Addario G, Pintilie M, Leighl NB et al. (2005) Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23: 2926–2936CrossRefPubMed D’Addario G, Pintilie M, Leighl NB et al. (2005) Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23: 2926–2936CrossRefPubMed
34.
Zurück zum Zitat Deppermann K-M (2001) Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 33 (Suppl): 115–120CrossRefPubMed Deppermann K-M (2001) Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 33 (Suppl): 115–120CrossRefPubMed
35.
Zurück zum Zitat Balducci L (2000) Geriatic oncology: challenges for the new century. Eur J Cancer 36: 1741–1754CrossRefPubMed Balducci L (2000) Geriatic oncology: challenges for the new century. Eur J Cancer 36: 1741–1754CrossRefPubMed
36.
Zurück zum Zitat Charlson ME, Popmpei P, Ales KL et al. (1987) A new method for classifying prognostic comorbidity in longitudinal studies. J Chronic Disease 40: 373–383CrossRef Charlson ME, Popmpei P, Ales KL et al. (1987) A new method for classifying prognostic comorbidity in longitudinal studies. J Chronic Disease 40: 373–383CrossRef
37.
Zurück zum Zitat Elder Lung Cancer Vinorelbine Italian Study (ELVIS) Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66–72CrossRefPubMed Elder Lung Cancer Vinorelbine Italian Study (ELVIS) Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91: 66–72CrossRefPubMed
38.
Zurück zum Zitat Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128: 947–57CrossRefPubMed Gridelli C, Shepherd FA (2005) Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 128: 947–57CrossRefPubMed
39.
Zurück zum Zitat Frasci G, Lorusso V, Panza N et al. (2000) Gemcitabine plus vinorelbine versus Vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18: 2529–2536PubMed Frasci G, Lorusso V, Panza N et al. (2000) Gemcitabine plus vinorelbine versus Vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18: 2529–2536PubMed
40.
Zurück zum Zitat Gridelli C, Perrone F, Gallo C et al. (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst 95: 362–372PubMed Gridelli C, Perrone F, Gallo C et al. (2003) Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst 95: 362–372PubMed
41.
Zurück zum Zitat Jackman DM, Lucca J, Fidias P et al. (2005) Phase II study of the EGFR tyrosine kinase inhibitor Erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung cancer. Lung Cancer 49 (Suppl 2): 62 (O-188)CrossRef Jackman DM, Lucca J, Fidias P et al. (2005) Phase II study of the EGFR tyrosine kinase inhibitor Erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung cancer. Lung Cancer 49 (Suppl 2): 62 (O-188)CrossRef
42.
Zurück zum Zitat Kelly K, Giarritta S, Akerley W et al. (2001) Should older patient receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology Trials 9505 and 9308. Proc Am Soc Clin Oncol 20: 329a Kelly K, Giarritta S, Akerley W et al. (2001) Should older patient receive combination chemotherapy for advanced stage non-small cell lung cancer? An analysis of Southwest Oncology Trials 9505 and 9308. Proc Am Soc Clin Oncol 20: 329a
43.
Zurück zum Zitat Langer CJ, Vangel J, Schiller DP et al. (2003) Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 22: 639 Langer CJ, Vangel J, Schiller DP et al. (2003) Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger patients (<70). Proc Am Soc Clin Oncol 22: 639
44.
Zurück zum Zitat Langer CJ, Manola J, Bernado P et al. (2002) Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173–181PubMed Langer CJ, Manola J, Bernado P et al. (2002) Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94: 173–181PubMed
45.
Zurück zum Zitat Fossella FV, Belani CP (2003) Phase III study of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin fort he first-line treatment of advanced/metastatic non-small cell lung cancer: analysis in elderly patients. Proc Am Soc Clin Oncol 22: 629 Fossella FV, Belani CP (2003) Phase III study of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin fort he first-line treatment of advanced/metastatic non-small cell lung cancer: analysis in elderly patients. Proc Am Soc Clin Oncol 22: 629
46.
Zurück zum Zitat Deppermann KM, Ukena D, von Pawel J et al. (2004) Vinorelbine and carboplatin in elderly patients with metastatic non-small cell lung cancer: a multicentre phase II study. Ann Oncol 15 (Suppl 3): iii183 (691P) Deppermann KM, Ukena D, von Pawel J et al. (2004) Vinorelbine and carboplatin in elderly patients with metastatic non-small cell lung cancer: a multicentre phase II study. Ann Oncol 15 (Suppl 3): iii183 (691P)
47.
Zurück zum Zitat Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25–32PubMed Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25–32PubMed
48.
Zurück zum Zitat Ranson M, Davidson N, Nicolson M et al. (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074–1080CrossRefPubMed Ranson M, Davidson N, Nicolson M et al. (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074–1080CrossRefPubMed
49.
Zurück zum Zitat Soria JC, Brisgand D, Le Chevalier T (2001) Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12: 1667–1670CrossRefPubMed Soria JC, Brisgand D, Le Chevalier T (2001) Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12: 1667–1670CrossRefPubMed
50.
Zurück zum Zitat Shepherd FA, Dancey J, Ramlau R et al. (2001) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103 Shepherd FA, Dancey J, Ramlau R et al. (2001) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095–2103
51.
Zurück zum Zitat Fossella FV, DeVore R, Kerr RN et al. (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18: 2354–2362PubMed Fossella FV, DeVore R, Kerr RN et al. (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group. J Clin Oncol 18: 2354–2362PubMed
52.
Zurück zum Zitat Hanna N, Shepherd FA, Fossella FV (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597CrossRefPubMed Hanna N, Shepherd FA, Fossella FV (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589–1597CrossRefPubMed
53.
Zurück zum Zitat Danson S, Middleton MR, O’Byrne KJ et al. (2003) Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer 98: 542–553CrossRefPubMed Danson S, Middleton MR, O’Byrne KJ et al. (2003) Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer 98: 542–553CrossRefPubMed
Metadaten
Titel
Nichtkleinzelliges Lungenkarzinom
Palliative Chemotherapie im Stadium IV und bei Patienten mit Komorbidität
verfasst von
Dr. M. Reck
K.M. Deppermann
U. Gatzemeier
N. Niederle
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 8/2006
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1081-z

Weitere Artikel der Ausgabe 8/2006

Der Onkologe 8/2006 Zur Ausgabe

Neu im Fachgebiet Onkologie

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.